Contraindicated (one)bortezomib will increase the degree or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Solid or average CYP2C19 inhibitors might enhance mavacamten systemic publicity, leading to coronary heart failure as a consequence of systolic dysfunction. Unlock 38% additional drug discovery time and do away with selection-producing do... https://shermann777bmx0.blog2news.com/profile